Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Author Correction: Decimated little brown bats show potential for adaptive change.

Auteri GG, Knowles LL.

Sci Rep. 2020 Mar 24;10(1):5674. doi: 10.1038/s41598-020-62444-7.

2.

Decimated little brown bats show potential for adaptive change.

Auteri GG, Knowles LL.

Sci Rep. 2020 Feb 20;10(1):3023. doi: 10.1038/s41598-020-59797-4. Erratum in: Sci Rep. 2020 Mar 24;10(1):5674.

3.

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.

Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N.

Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20.

PMID:
31860137
4.

Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years.

Palandri F, Santoro C, Carpenedo M, Cantoni S, Barcellini W, Carli G, Carrai V, Rossi E, Rivolti E, Lucchesi A, Rotondo F, Baldacci E, Auteri G, Sutto E, Di Pietro C, Catani L, Bartoletti D, De Stefano V, Ruggeri M, Mazzucconi MG, Cavo M, Rodeghiero F, Vianelli N.

Thromb Res. 2020 Jan;185:88-95. doi: 10.1016/j.thromres.2019.11.026. Epub 2019 Nov 21.

PMID:
31783273
5.

Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.

Iurlo A, Elli EM, Palandri F, Cattaneo D, Bossi A, Cortinovis I, Bucelli C, Orofino N, Brioschi F, Auteri G, Bianchi P, Fabris S, Isimbaldi G, Sabattini E, Baldini L, Gianelli U.

Hematol Oncol. 2019 Oct;37(4):424-433. doi: 10.1002/hon.2658. Epub 2019 Aug 22.

PMID:
31359447
6.

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.

Hematol Oncol. 2019 Oct;37(4):418-423. doi: 10.1002/hon.2619. Epub 2019 Jun 7.

PMID:
30985017
7.

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.

Fattizzo B, Pasquale R, Carpenedo M, Cantoni S, Auteri G, Gramegna D, D'Adda M, Napolitano M, Consonni D, Ruggeri M, Siragusa S, Rossi G, Vianelli N, Barcellini W.

Haematologica. 2019 Oct;104(10):e470-e473. doi: 10.3324/haematol.2019.216804. Epub 2019 Mar 7. No abstract available.

8.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
9.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542
10.

Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis.

Barone M, Ricci F, Sollazzo D, Ottaviani E, Romano M, Auteri G, Bartoletti D, Reggiani MLB, Vianelli N, Tazzari PL, Cavo M, Forte D, Palandri F, Catani L.

Br J Haematol. 2019 Jun;185(5):987-991. doi: 10.1111/bjh.15682. Epub 2018 Nov 18. No abstract available.

PMID:
30450539
11.

Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients.

Palandri F, Catani L, Auteri G, Bartoletti D, Fatica S, Fusco A, Bacchi Reggiani ML, Cavo M, Vianelli N.

Br J Haematol. 2019 Feb;184(3):424-430. doi: 10.1111/bjh.15668. Epub 2018 Nov 8.

PMID:
30408157
12.

A long winter for the Red Queen: rethinking the evolution of seasonal migration.

Winger BM, Auteri GG, Pegan TM, Weeks BC.

Biol Rev Camb Philos Soc. 2019 Jun;94(3):737-752. doi: 10.1111/brv.12476. Epub 2018 Nov 4. Review.

PMID:
30393938
13.

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G.

Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5. No abstract available.

PMID:
30321784
14.

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34+ Cells.

Forte D, Sollazzo D, Barone M, Allegri M, di Martella Orsi A, Romano M, Sinigaglia B, Auteri G, Vianelli N, Cavo M, Palandri F, Catani L.

Mediators Inflamm. 2018 Jul 4;2018:5974613. doi: 10.1155/2018/5974613. eCollection 2018.

15.

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.

Palandri F, Auteri G, Baccarani M.

Hematol Oncol. 2017 Jun;35(2):145-150. doi: 10.1002/hon.2324. Epub 2016 Aug 10. Review.

PMID:
27510853
16.

Prevalence of infections caused by AIDS and hepatitis B viruses in jailed people.

Crovari P, Cassini U, Infante D, Guano F, Icardi GC, Auteri G, Di Ponzio A, Cuneo Crovari P.

Boll Ist Sieroter Milan. 1985;64(5):367-70.

PMID:
3004543
17.

Increasing prevalence of HTLV-III infection in intravenous drug users in Liguria, Italy.

Cuneo Crovari P, Terragna A, Robert L, Orlando G, Rizzo F, Piuma-Fusco M, Icardi GC, Papa D, Di Ponzio A, Auteri G, et al.

Boll Ist Sieroter Milan. 1985;64(4):339-42.

PMID:
3000406
18.

Expression of glial fibrillary acidic protein, actin, fibronectin and factor VIII antigen in human astrocytomas.

Lolait SJ, Harmer JH, Auteri G, Pedersen JS, Toh BH.

Pathology. 1983 Oct;15(4):373-8.

PMID:
6326028

Supplemental Content

Loading ...
Support Center